Imbed Biosciences’ Team Members Honored in List of Health Innovators

Madison, WI, November 7, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, is pleased to share that two of its team members—Jeffrey Dalsin, Ph.D. and Robert Beckman—have been named to the 2017 edition of Madison Magazine’s prestigious M-List.  This year, the M-List honors health innovators.  Dr. Dalsin serves as Imbed’s Vice President of Product Development, while Mr. Beckman serves as an outside director on the company’s Board of Directors.

Dr. Dalsin has spent his professional career developing medical technology and serving in leadership roles in start-up companies in Madison. Prior to joining Imbed a little over a year ago, Jeff previously helped cofound Nerites Corporation, a start-up that commercialized an innovative surgical adhesive and served as Director of Product Development. In that role, Jeff wore many hats and gained broad start-up operational experience through the company’s successful acquisition in 2011. Most recently, he led a start-up ultrasound technology company. “I am honored and humbled to be included with such an esteemed group. I look forward to continuing to help make Madison a leader in health technology,” Dalsin said.

Mr. Beckman, in addition to begin a company director, is currently President and CEO of Wicab Inc, a medical device company developing an assistive device for visually impaired. The device translates digital information from a video camera into gentle electrical stimulation patterns on the surface of the tongue. After a pivotal clinical study, Wicab recently obtained regulatory approvals for marketing the device in the U.S. and Western Europe.  Mr. Beckman was vice president and chief financial officer of Lunar Corp., Madison, WI, and later, of Bone Care International, Middleton, WI. Lunar Corp made machines to screen for bone density, and was acquired by GE Medical in 2000. Bone Care developed drugs to treat a condition that can lead to bone damage in kidney patients, and was bought by Genzyme in 2005.

“Imbed is proud to have two leaders in health innovation among its very talented team.  Both Jeff and Bob bring great experience to our effort, and will be key in ensuring Imbed’s success as the company continues to bring MircoLyte Ag, our FDA-cleared antimicrobial wound dressing, and other innovative products to market,” said Ankit Agarwal, President and CEO of Imbed Biosciences.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation.